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Abstract
Isolated mitochondrial complex II deficiency is a rare cause of mitochondrial respiratory chain disease. To date biallelic
variants in three genes encoding mitochondrial complex II molecular components have been unequivocally associated with
mitochondrial disease (SDHA/SDHB/SDHAF1). Additionally, variants in one further complex II component (SDHD) have
been identified as a candidate cause of isolated mitochondrial complex II deficiency in just two unrelated affected individuals
with clinical features consistent with mitochondrial disease, including progressive encephalomyopathy and lethal infantile
cardiomyopathy. We present clinical and genomic investigations in four individuals from an extended Palestinian family
with clinical features consistent with an autosomal recessive mitochondrial complex II deficiency, in which our genomic
studies identified a homozygous NM_003002.3:c.[205 G > A];[205 G > A];p.[(Glu69Lys)];[(Glu69Lys)] SDHD variant as
the likely cause. Reviewing previously published cases, these findings consolidate disruption of SDHD function as a cause
of mitochondrial complex II deficiency and further define the phenotypic spectrum associated with SDHD gene variants.
Introduction
The mitochondrial oxidative phosphorylation (OXPHOS)
system is composed of five multi-subunit transmembrane
protein complexes (I–V) encoded by the mitochondrial and
nuclear genomes, and is the primary mechanism for ade-
nosine triphosphate production in eukaryotic cells.
OXPHOS defects result in mitochondrial disease, with an
estimated prevalence of 1:4300 [1, 2].
Mitochondrial complex II (succinate dehydrogenase) is
composed of two catalytic subunits (SDHA/SDHB)
anchored to the inner mitochondrial membrane by two
smaller subunits (SDHC/SDHD) [3, 4]. Complex II differs
from other mitochondrial respiratory chain complexes, in
that the four structural subunits and their two assembly
factors (SDHAF1/SDHAF2) are solely encoded by the
nuclear genome. Complex II is also unique in being
involved in both the mitochondrial respiratory chain and the
Krebs cycle [2].
Mitochondrial complex II deficiency with multisystem
involvement has been reported in association with biallelic
SDHA [5], SDHB [2], SDHD [6, 7] and SDHAF1 [3, 8] gene
variants, with clinical presentations including Leigh syndrome,
leukoencephalopathy, optic atrophy and cardiomyopathy with
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highly variable severity and age of onset [5, 9]. Complex II
deficiency is rare accounting for only 2–4% of OXPHOS
defects [6], with variants in SDHA being most common, pre-
dominantly associated with Leigh syndrome [5]. Previously,
only two individuals with candidate biallelic SDHD variants
and isolated complex II deficiency have been reported [6, 7].
Here we describe four Palestinian siblings presenting in
childhood with clinical features indicative of mitochondrial
disease and a likely pathogenic homozygous SDHD variant,
consolidating SDHD gene variants as a likely cause of auto-
somal recessive mitochondrial complex II deficiency.
Materials and methods
Blood samples were collected with informed consent
(Palestinian Health Research Council; PHRC/HC/518/19).
Single-nucleotide polymorphism (SNP) genotyping was
performed (HumanCytoSNP-12 v2.1 Beadchip array: Illu-
mina). Whole-exome sequencing (WES) (NextSeq1500:
Illumina) analysis involved: Agilent SureSelect Whole
Exome v6 targeting, read alignment (BWA-MEM,v0.7.17),
mate-pairs fixed and duplicates removed (Picard v2.15.0),
InDel realignment and base quality recalibration (GATK
v3.7.0), SNVs/InDels (GATK/HaplotypeCaller), annotation
using Alamut Batch (v1.10) and CNV detection with Exo-
meDepth [10] and Savvy CNV [11]. Dideoxy sequencing
was undertaken using standard techniques.
Model 3abv (porcine heart mitochondrial complex II) [12]
was selected from X-ray diffraction/NMR-derived structures
of SDHD (O14521) and its homologues (RCSB Protein Data
Bank). Amino acid residues were visualised with their polar
bonds, and annotated using Pymol 2.3 [13, 14].
Results
Clinical findings
We describe four affected Palestinian patients (three male,
one female) aged 4–20 years, comprising of two sibships
from an extended interconnecting family (Fig. 1A). All four
children presented with developmental delay in infancy and
variable clinical and laboratory findings suggestive of a
Fig. 1 Family pedigree showing SDHD c.205 G >A genotype data,
neuroimaging and images of affected individuals. A Pedigree dia-
gram showing segregation of the SDHD c.205 G >A; p.(Glu69Lys)
variant. Genotypes are shown beneath generations IV and V (+, c.205
G > A; −, WT). Affected individuals were homozygous for SDHD
c.205 G > A, DNA was available from all but one affected individual
(V:5). B Electropherogram showing the DNA sequence at the position
of SDHD c.205 G >A in a homozygous affected individual. C T1- and
T2-weighted axial views of MRI head of individual V:2 (aged
8 months). Normal myelination and no intracranial abnormalities.
D Image of affected individual V:4, illustrating the absence of
any facial dysmorphism. E (i) Schematic localisation of SDHD
p.(Glu69Lys), p.(Asp92Gly) and p.(Ter160LeuextTer3) variants
within the succinate dehydrogenase cytochrome b small subunit
(CybS) domain of the SDHD polypeptide. The orange rectangle
denotes the transit peptide (TP) domain, the red circle denotes the iron
(haem axial ligand) binding site shared with SDHC and the blue circle
denotes the ubiquinone binding site shared with SDHB. (ii) Con-
servation of the SDHD p.(Glu69Lys), p.(Asp92Gly) and p.(Ter160-
LeuextTer3) variants across species. F Visual depiction of the two
autozygous regions on chromosome 11 (shown in red) common to
affected individuals V:2, V:4 and V:6 including the 2.37Mb region
containing 21 genes including SDHD.
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mitochondrial disorder including elevated serum lactate/
urinary Krebs cycle metabolites, nystagmus, optic atrophy,
progressive microcephaly, generalised hypotonia, epileptic
seizures, severe/profound intellectual disability/develop-
mental impairment and cardiomyopathy. The affected
children were not dysmorphic (Fig. 1C), though individuals
V:2 and V:4 were noted to have significant hypertrichosis,
particularly over their back and limbs. MRI neuroimaging
was unremarkable for one child at 8 months (V:2; Fig. 1D),
however, his sister’s scan revealed delayed myelination at
age 6 months (V:4). Hirschsprung disease, confirmed by
aganglionic rectal biopsy, was noted in a single individual
(V:2). A full description of the clinical features and disease
progression is summarised in Table 1.
Genetic findings and homology modelling
Genome-wide SNP genotyping and WES were undertaken
assuming that a homozygous founder variant was respon-
sible, although also considering other genetic mechanisms.
SNP genotyping (individuals V:2, V:4 and V:6) identified
four notable (>1Mb) shared homozygous regions, the two
largest identified on chromosome 11; a ~7.00Mb region
(rs6485795–rs11246414, Chr11:g.47908294–54905443
[hg38]) and a ~2.42Mb region (rs120436–rs12794326,
Chr11:g.110826521–113248134) (Fig. 1F). WES was per-
formed on DNA from affected individual V:4, to identify
rare functional candidate variants. Variants were prioritised
by call quality and frequency (gnomAD v2.1.1/1000 Gen-
omes Project, MAF ≤ 0.0001) and cross referenced with
SNP data, identifying only a single candidate homozygous
variant of relevance to the phenotype in SDHD NM_003002.3:
c.[205G >A];[205G >A];p.[(Glu69Lys)];[(Glu69Lys)];Chr11:
g.[112088902G > A];[112088902G > A], located within the
second largest shared homozygous region. The variant is
present in only two heterozygotes in gnomAD (v2.1.1) and
is predicted to result in a glutamic acid—lysine substitution
in an evolutionarily conserved Glu69 residue (Fig. 1E). This
variant was previously reported as the likely candidate
cause of disease in compound heterozygous form ((c.[205G
> A];[479G > T]; p.[(Glu69Lys)];[(Ter160LeuextTer3)])) in
a single individual with autosomal recessive encephalo-
myopathy and isolated mitochondrial complex II defi-
ciency [6] (ClinVar accession:VCV000156153.8 and
SCV001424558). Dideoxy sequencing confirmed cose-
gregation as appropriate for an autosomal recessive disorder
(Fig. 1A, B ). Protein modelling positions the p.(Glu69Lys)
substitution within the first transmembrane alpha helix,
where it likely disrupts tertiary structure through interrupt-
ing a predicted hydrogen bond with Gln109 on the adjacent
helix (Supplementary Fig. S1A). Conversely, a previously
described variant, p.(Asp92Gly) is located at the apex
of transmembrane alpha helices one and two, in close
proximity to the membrane and inter-membrane space
(Supplementary Fig. S1A, B).
Discussion
Here we define a homozygous SDHD c.[205G > A];
[205G > A];p.[(Glu69Lys)];[(Glu69Lys)] missense var-
iant as the likely cause of isolated mitochondrial com-
plex II deficiency in three affected children from an
extended Palestinian family. DNA was unavailable for
V:5 (deceased age 10 years), whose clinical history
overlapped that of his sibling (V:6). Tissues and organs
heavily dependent on robust OXPHOS processes tend to
be most affected by mitochondrial disease [15],
explaining why common findings include optic atrophy,
leukoencephalopathy, myopathy, cardiomyopathy and
Leigh syndrome. These clinical features overlap those
described in the two individuals with SDHD-related
mitochondrial disease reported to date (Table 1). Pre-
viously, compound heterozygous variants in SDHD [6],
including the same p.(Glu69Lys) variant identified here
and a c.479G > T; p.(Ter160LeuextTer3) alteration (c.
[205G > A];[479G > T];p.[(Glu69Lys)];[(Ter160Leuext-
Ter3)]), were identified as the likely candidate cause of
disease in a Swiss child presenting with developmental
regression following a viral infection, at 3 months.
Progressive ocular (visual impairment, nystagmus, optic
disc pallor) and neurological (epileptic seizures, ataxia,
dystonia and continuous intractable myoclonic move-
ment) involvement were described, and the child died
aged 10 years. Urinalysis revealed lactic aciduria, keto-
nuria and Krebs cycle intermediates. Complex II activity
was deficient in skeletal muscle and complementation
studies in patient fibroblasts showed restoration of
complex II assembly and function with expression of
wildtype, but not mutant, SDHD cDNA [6]. Subse-
quently an Irish male infant was described [7] homo-
zygous for a novel SDHD c.[275A > G];[275A > G];p.
[(Asp92Gly)];[(Asp92Gly)] substitution, presenting with
cardiomyopathy in utero. He developed cardiopulmonary
insufficiency rapidly after birth, dying on day 1 of life.
Subsequent analysis of respiratory chain function in
patient muscle homogenate revealed a marked defect in
complex II activity.
The four affected individuals described here show
phenotypic overlap with both these individuals (Table 1).
Our study extends the clinical spectrum and highlights
the wide range of phenotypical features and severity
across affected individuals, even those with the same
SDHD genotype (Table 1). Hypertrichosis, a recognised
feature of some forms of mitochondrial disease (most
notably SURF1-Leigh syndrome [16]), was a noted






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Consolidating biallelic SDHD variants as a cause of mitochondrial complex II deficiency
feature in two Palestinian children. Hirschsprung disease
diagnosed in a single affected individual (V:2) has not
been previously reported in association with SDHD var-
iants, and it remains unclear whether this is an associated
or unrelated feature. Neurodevelopmental regression is a
common characteristic of mitochondrial disease, parti-
cularly during physiologic stress through intercurrent
infection, prolonged fasting or dehydration [17]. It is thus
unsurprising that this appears to be a common feature of
complex II deficiency due to biallelic SDHD variants
(Table 1). An accurate molecular diagnosis for complex II
deficient patients would support avoidance of prolonged
fasting and dehydration.
Homology modelling of the two putative pathogenic
SDHD missense variants thus far associated with isolated
autosomal recessive mitochondrial complex II deficiency [c.
[205G > A];p.(Glu69Lys) and c.[275A > G];p.(Asp92Gly)]
predicts disruption of non-covalent bonds between trans-
membrane helices and changes to complex II positioning in
the inner mitochondrial membrane as likely outcomes
(Supplementary Fig. S1a). In addition to their role in pri-
mary mitochondrial disease, heterozygous germline variants
in other complex II subunits and assembly factors (includ-
ing SDHA, SDHB, SDHC, SDHD and SDHAF2) are asso-
ciated with paragangliomas, phaeochromocytomas and
gastrointestinal stromal tumours [3]. None of the three
SDHD variants associated with mitochondrial complex II
deficiency have been previously linked to tumourigenesis,
including in this extended Palestinian family, although a
Dutch founder familial paraganglioma SDHD variant
c.274G > T; p.(Asp92Tyr) has been described [18]. Addi-
tionally, SDHA and SDHB variants have been associated
with both mitochondrial complex II deficiency in biallelic
form, and hereditary cancer susceptibility in monoallelic
form [5, 19]. Therefore routine surveillance of heterozygous
SDHD carriers is suggested for early detection of para-
gangliomas and phaeochromocytomas and appropriate
intervention. Together the data presented here consolidate
biallelic SDHD variants as a cause of mitochondrial disease
due to mitochondrial complex II malfunction, and extend
the variable associated clinical features.
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